T2DM (Type 2 Diabetes Mellitus)
56
7
13
22
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
3.6%
2 terminated out of 56 trials
91.7%
+5.2% vs benchmark
30%
17 trials in Phase 3/4
14%
3 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (56)
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets
Detecting Type 2 Diabetes From Voice
Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type 2 Diabetes Mellitus
Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets
Duodenal ReCET for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease
Comparison of 3 Versus 6-Month Use of CGMS in Non-Insulin Using T2DM Patients
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM
Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D
Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine
Virtual Diabetes Group Visits Across Health Systems
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
Glycemia and Antibiotic Efficacy in Diabetic Recurrent UTIs
Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers